Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily C Gantman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Huntington'S Disease|April 25, 2022
Huntington's Disease Regulatory Science Consortium: Accelerating Medical Product DevelopmentEmily C Turner, Emily C Gantman, Cristina Sampaio, et al.
Journal of Huntington'S Disease|April 24, 2023
Applying the Huntington's Disease Integrated Staging System (HD-ISS) to Observational StudiesJeffrey D Long, Emily C Gantman, James A Mills, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 5, 2024
Time to Functional Loss as an Endpoint in Huntington's Disease Trials: Enrichment and Sample SizeJames A Mills, Jeffrey D Long, Jatin G Vaidya, et al.
Frontiers in Neurology|October 8, 2021
Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary ReviewKirsi M Kinnunen, Adam J Schwarz, Emily C Turner, et al.
European Journal of Immunology|August 9, 2014
T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activationNathalie E Blachère, Dana E Orange, Bianca D Santomasso, et al.
Frontiers in Neurology|November 8, 2021
Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical TrialsKirsi M Kinnunen, Ariana P Mullin, Dorian Pustina, et al.
JCI Insight|November 3, 2017
T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergyNathalie E Blachère, Dana E Orange, Emily C Gantman, et al.
The Lancet. Neurology|June 18, 2022
A biological classification of Huntington's disease: the Integrated Staging SystemSarah J Tabrizi, Scott Schobel, Emily C Gantman, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Huntington'S Disease|April 25, 2022
Huntington's Disease Regulatory Science Consortium: Accelerating Medical Product DevelopmentEmily C Turner, Emily C Gantman, Cristina Sampaio, et al.
Journal of Huntington'S Disease|April 24, 2023
Applying the Huntington's Disease Integrated Staging System (HD-ISS) to Observational StudiesJeffrey D Long, Emily C Gantman, James A Mills, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 5, 2024
Time to Functional Loss as an Endpoint in Huntington's Disease Trials: Enrichment and Sample SizeJames A Mills, Jeffrey D Long, Jatin G Vaidya, et al.
Frontiers in Neurology|October 8, 2021
Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary ReviewKirsi M Kinnunen, Adam J Schwarz, Emily C Turner, et al.
European Journal of Immunology|August 9, 2014
T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activationNathalie E Blachère, Dana E Orange, Bianca D Santomasso, et al.
Frontiers in Neurology|November 8, 2021
Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical TrialsKirsi M Kinnunen, Ariana P Mullin, Dorian Pustina, et al.
JCI Insight|November 3, 2017
T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergyNathalie E Blachère, Dana E Orange, Emily C Gantman, et al.
The Lancet. Neurology|June 18, 2022
A biological classification of Huntington's disease: the Integrated Staging SystemSarah J Tabrizi, Scott Schobel, Emily C Gantman, et al.
Pageof 1